Daytrana

Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight; 2020 to 2026 - ResearchAndMarkets.com

Retrieved on: 
星期五, 一月 31, 2020
Health, Pharmaceutical, Pharmacology, Health, Dosage forms, Routes of administration, Transdermal patch, Granisetron, Transdermal, Chemotherapy-induced nausea and vomiting, Dermal patch, Hisamitsu Pharmaceutical, Daytrana

The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report also discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market and highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
  • Global Transdermal Patch Market Opportunity: > US$ 15 Billion
    Global Transdermal Patch Clinical Pipeline: 100 Patches In Trials
    Global Transdermal Patch Clinical Trials Insight by Company, Drug Class, Indication & Patent Information
    Regional Trends & Market Insight: US, Europe & Asia-Pacific
    Since the advent of the transdermal drug delivery technique, there has been a continuous rise in the market of transdermal patches globally.
  • For instance, granisetron transdermal system is a transdermal patch used to treat chemotherapy-induced nausea and vomiting in a regulated way.

Global Transdermal Patch Industry Outlook and Forecast 2020-2026: Dosage & Price Insights, Clinical Trials by Company, Drug Class, Indication & Patent Information

Retrieved on: 
星期五, 一月 17, 2020
Pharmacology, Health sciences, Health, Routes of administration, Dosage forms, Transdermal patch, Transdermal, Dermal patch, Hisamitsu Pharmaceutical, Daytrana

DUBLIN, Jan. 17, 2020 /PRNewswire/ -- The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 17, 2020 /PRNewswire/ -- The "Global Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The report also discusses the ongoing clinical and non-clinical parameters with respect to development of global transdermal patch market and highlights the need for integration of transdermal patches in existing drug delivery methodology available to pharmaceutical companies.
  • Global Transdermal Patch Market Opportunity: > US$ 15 Billion
    Global Transdermal Patch Clinical Pipeline: 100 Patches In Trials
    Global Transdermal Patch Clinical Trials Insight by Company, Drug Class, Indication & Patent Information
    Regional Trends & Market Insight: US, Europe & Asia-Pacific
    Since the advent of the transdermal drug delivery technique, there has been a continuous rise in the market of transdermal patches globally.
  • The need of transdermal patch drug delivery has already gained momentum and is sure to play its part in the global pharmaceutical market.

Now Available - JORNAY PM™ (Methylphenidate HCl) CII, the First and Only ADHD Stimulant Dosed in the Evening

Retrieved on: 
星期二, 六月 18, 2019
Health, Clinical trials, Pharmaceutical, Psychoactive drugs, Drugs, Medicine, Stimulants, Nootropics, RTT, Amphetamine, Methylphenidate, Attention deficit hyperactivity disorder, Pemoline, Adverse effect, Daytrana, Health, Clinical trials, Pharmaceutical, Psychoactive drugs, Drugs, Medicine, Stimulants, Nootropics, RTT, Amphetamine, Methylphenidate, Attention deficit hyperactivity disorder, Pemoline, Adverse effect, Daytrana

JORNAY PM is a CNS stimulant approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in patients 6 years and older.

Key Points: 
  • JORNAY PM is a CNS stimulant approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in patients 6 years and older.
  • The evening administration of a stimulant medication is made possible by DELEXIS, Ironshores novel drug delivery platform.
  • JORNAY PM was well tolerated in clinical trials with a safety profile generally consistent with other methylphenidate products.
  • Additional adverse reactions in pediatric patients 6 to 12 years treated with JORNAY PM: headache, psychomotor hyperactivity, and mood swings.